Intrexon (XON) Misses Q3 EPS by 11c, Revenues Miss

Intrexon (NASDAQ: XON) reported Q3 EPS of ($0.35), $0.11 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $23.04 million versus the consensus estimate of $33 million.

"Intrexon's longstanding focus on Health and, in particular, in cancer therapeutics may be vindicated as Precigen's clinical programs further develop," commented Mr. Kirk.

Mr. Kirk concluded, "When I became CEO in 2009, when the company entered into its first collaboration in 2011, when it IPO'd in 2013 and through last year's reacquisition of the vast majority of its commercial rights pertaining to its cancer therapeutics programs, healthcare has been our greatest area of investment and potential. When Helen Sabzevari joined us in 2017 as President of Precigen, truly the repository of the original Intrexon technology as well as its most substantial technology acquisitions, we saw great potential if these technologies could be unlocked by a great drug development team. Today we begin to share with the world what Helen and her team have accomplished and, equally importantly, to let you hear this formidable pharmaceutical executive tell you this in her own words."

For earnings history and earnings-related data on Intrexon (XON) click here.

You May Also Be Interested In

• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15